• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence.

作者信息

Ferrari Serge

机构信息

Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.

出版信息

J Bone Miner Res. 2020 Jul;35(7):1205-1206. doi: 10.1002/jbmr.4022. Epub 2020 Apr 21.

DOI:10.1002/jbmr.4022
PMID:32315077
Abstract
摘要

相似文献

1
Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence.地诺单抗停药后使用唑来膦酸：部分缓解但仍无把握。
J Bone Miner Res. 2020 Jul;35(7):1205-1206. doi: 10.1002/jbmr.4022. Epub 2020 Apr 21.
2
Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.在狄诺塞麦停药期间以及随后早期或晚期输注唑来膦酸过程中循环骨硬化蛋白水平。
Endocrine. 2021 Jul;73(1):223-225. doi: 10.1007/s12020-021-02666-5. Epub 2021 Mar 2.
3
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.唑来膦酸/地舒单抗治疗后骨丢失：双膦酸盐的作用。
Calcif Tissue Int. 2018 Jul;103(1):55-61. doi: 10.1007/s00223-018-0404-6. Epub 2018 Feb 14.
4
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.地诺单抗在未经治疗及曾用唑来膦酸治疗的低骨量绝经后女性中的应用：对骨密度和骨转换标志物的影响。
Metabolism. 2015 Oct;64(10):1291-7. doi: 10.1016/j.metabol.2015.06.018. Epub 2015 Jun 27.
5
Bone Loss After Denosumab: Only Partial Protection with Zoledronate.地舒单抗治疗后发生的骨丢失：唑来膦酸仅提供部分保护。
Calcif Tissue Int. 2017 Oct;101(4):371-374. doi: 10.1007/s00223-017-0288-x. Epub 2017 May 13.
6
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.唑来膦酸预防停用地舒单抗治疗的女性骨丢失：一项前瞻性 2 年临床试验。
J Bone Miner Res. 2019 Dec;34(12):2220-2228. doi: 10.1002/jbmr.3853. Epub 2019 Oct 14.
7
Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.唑来膦酸与地舒单抗对低骨量初治绝经后妇女血清骨硬化蛋白和 Dickkopf-1 水平的比较影响：一项随机、头对头临床试验。
J Clin Endocrinol Metab. 2013 Aug;98(8):3206-12. doi: 10.1210/jc.2013-1402. Epub 2013 Jun 20.
8
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.唑来膦酸对罗莫单抗/地诺单抗治疗后骨质流失的影响：2年随访
Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17.
9
Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.唑来膦酸与地诺单抗治疗骨质疏松症的疗效、不良反应及成本比较。
Endocr Pract. 2015 Mar;21(3):275-9. doi: 10.4158/EP14106.OR.
10
Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting.
J Clin Rheumatol. 2023 Mar 1;29(2):101-104. doi: 10.1097/RHU.0000000000001894. Epub 2022 Aug 18.

引用本文的文献

1
A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.一项多机构随机对照试验，旨在研究唑来膦酸是否能预防地诺单抗停用后的骨质流失：地诺单抗序贯治疗（DST）试验的研究方案。
Front Med (Lausanne). 2021 Sep 8;8:717168. doi: 10.3389/fmed.2021.717168. eCollection 2021.
2
Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.成骨不全症和 McCune-Albright 综合征中地舒单抗治疗和停药的安全性：一项观察性研究。
J Bone Miner Res. 2021 Sep;36(9):1729-1738. doi: 10.1002/jbmr.4380. Epub 2021 Jun 10.